Navigation Links
Cell Therapeutics, Inc. Announces Exercise of Overallotment
Date:7/23/2009

SEATTLE, July 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) ("CTI" or the "Company") today announced that the underwriter of its previously announced public offering of 29,332,107 shares of its common stock and warrants to purchase up to 7,333,027 shares of its common stock has exercised in full its option to purchase 4,399,816 additional shares of its common stock and warrants to purchase up to 1,099,954 additional shares of its common stock to cover overallotments. The exercise of the underwriter's overallotment option results in the issuance in this offering of an aggregate of 33,731,923 shares of its common stock and warrants to purchase up to 8,432,981 shares of its common stock, for aggregate gross proceeds of approximately $43.9 million. The net proceeds to the Company after deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $40.3 million.

Each warrant has an exercise price of $1.70 per warrant share, for total potential additional gross proceeds to the Company of approximately $14.3 million upon exercise of the warrants. The warrants are exercisable immediately upon the date of issuance and will expire nine months thereafter.

As previously announced, the Company expects to close the offering on or about July 28, 2009, subject to customary conditions, at which time the Company will receive the cash proceeds from the offering and deliver the securities.

Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as sole book-running manager for the offering. In addition, Trout Capital LLC acted as financial advisor to the Company. The offering was conducted as a public offering pursuant to the Company's shelf registration statement
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
2. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
3. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
4. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
5. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
6. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
7. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
8. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
9. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
10. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
11. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Beckman Coulter , a global leader ... renewed its agreement with Personify for an ... Personify will continue to streamline the Beckman Coulter talent ... including time-to-fill, time-to-source and a deep reduction to cost-per-hire. ... was based on the success of our partnership over ...
(Date:9/17/2014)... MA (PRWEB) September 17, 2014 ... Safety (ACRES) , a multi-stakeholder non-profit collaborative building ... efficiency in clinical research, today announced Phase 3 ... , Amir H. Kalali, Vice-President, ... and Arti Bajpai, President, Compliance and Quality Integration ...
(Date:9/16/2014)... September 16, 2014 --The emerging field of molecular ... the next level, enabling the construction of tiny ... devices, individual molecules would take on the roles ... , A team of researchers from five Japanese ... for use in small-scale electronics: a molecule called ...
(Date:9/16/2014)... , Sept. 16, 2014  Donald Fresne, President and ... of Stephan Vagner , PhD to its Scientific Advisory ... of Toulouse, France , performed research at ... , and at Inserm, the French institute of health and ... works both at the Curie Institute, Orsay, France ...
Breaking Biology Technology:Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4The future face of molecular electronics 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2
... a leading global,full-service contract research organization, announced it ... Clinical Pharmacology., Dr. Wei joins Medpace with ... early phase cardio-metabolic studies. He will consult,with sponsors ... to which studies merit inclusion in the programs ...
... today announced that it has appointed Mr. Jorge,Cantonnet to ... effective as of 1 February 2008. Mr. Cantonnet is ... agro-biotechnology company listed on OTCBB in Dec 2007,(OTC Bulletin ... million in fiscal year ended 30 September 2007, with ...
... and SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ - MIGENIX ... drugs for infectious,diseases, will add a 600mg celgosivir ... viral kinetics study in hepatitis C virus,("HCV") treatment-naive ... Health Canada and Institutional Review Board (IRB) approvals. ...
Cached Biology Technology:Medpace Hires Clinical Pharmacologist, Jim Wei, MD, PhD 2China Agro-Technology Appoints New CEO 2China Agro-Technology Appoints New CEO 3MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 2MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 3MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 4MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 5MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 6
(Date:9/16/2014)... Columbia Center for Children,s Environmental Health at the Mailman ... an association between childhood asthma and prenatal exposure to ... products. Results appear online in the journal Environmental ... exposed during pregnancy to higher levels of the chemicals, ... 72 percent and 78 percent increase in risk of ...
(Date:9/16/2014)... 17, 2014)The North American Menopause Society (NAMS) has ... care of midlife womenon everything from hot flashes ... American Menopause Society Recommendations for Clinical Care of ... Society,s journal Menopause . This is the ... care of midlife women freely available to all ...
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
... Suppressing a cellular cleanup-mechanism known as autophagy can ... neural degeneration. In an upcoming issue of Autophagy, scientists ... the first time that the opposite is true as ... flies prevented the age-dependent accumulation of cellular damage in ...
... lifeless lakeshore lapped by waves, floating algae learned to survive ... the Earth into a green paradise. The secrets of ... to the sequencing of a modern descendent of these first ... on recently exposed shorelines, quickly fruits, and then dies. ...
... collection of genes the genome of a ... link between single-celled algae and flowering plants. Just ... understand human genomic history, the sequencing of plant genomes ... kingdom, according to Ralph S. Quatrano, Ph.D., the Spencer ...
Cached Biology News:Aging gracefully requires taking out the trash 2Aging gracefully requires taking out the trash 3Moss genome shows how plants invaded the land and learned to survive heat and drought 2Moss genome shows how plants invaded the land and learned to survive heat and drought 3WUSTL researchers spearhead key genome initiative 2WUSTL researchers spearhead key genome initiative 3WUSTL researchers spearhead key genome initiative 4
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
SHEEP ANTI FLECAINIDE...
ANTI PIG LDH H4...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: